Original Research

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S

Therapeutics and Clinical Risk Management 2016, 12:1667-1675

Published Date: 11 November 2016